Cinclus Pharma (CINPHA) Q3 2025 earnings summary

Executive summary

• Phase III HEEALING 1 trial for linaprazan glurate initiated in Europe, with first patient dosed in October 2025 and recruitment progressing as planned across seven countries, targeting severe erosive GERD with high unmet need.

• Linaprazan glurate demonstrates superior 24-hour acid control and fastest onset in class, with positive regulatory feedback in Europe and the U.S. supporting NDA preparation and CMC strategy alignment.

• Strategic partnerships and licensing agreements secured with Zentiva for Europe (valued up to EUR 220 million plus royalties) and Sinorda for Asia, with licensing revenue recognized.

• Linaprazan glurate approved in China, with launch expected in 2026 pending pricing and reimbursement approval.

• PCABs, including linaprazan glurate, are rapidly gaining global traction, displacing PPIs in key markets and supported by evolving clinical guidelines.

Financial highlights

• Net sales for Q3 2025 were SEK 9.7 million, mainly from Zentiva licensing revenue; Jan–Sep 2025 net sales reached TSEK 43,839.

• Operating loss for Q3 2025 was SEK -44.1 million; net loss SEK -40.7 million, both higher year-over-year due to increased R&D spending.

• Cash and cash equivalents at period end were SEK 540.2 million, supporting operations into 2027 and through Phase III readout.

• R&D expenses for Q3 2025 were SEK 45.6 million, representing 86% of total operating expenses.

• Equity at period end was SEK 429.9 million, with non-current and current liabilities reflecting contract liabilities from the Zentiva deal.

Outlook and guidance

• Topline results from HEEALING 1 Phase III study expected in the second half of 2026.

• Financial runway extends into 2027, covering key clinical milestones; additional financing will be needed for further studies and indications.

• Additional clinical sites and studies, including in the U.S., planned to ensure timely completion and expansion.

• Anticipated China launch in 2026 pending price and reimbursement process.